Biotech company specializing on progressing psychedelic therapeutics Cybin Inc. (OTCMKTS: CLXPF) has inked a drug development agreement deal with New Jersey based Catalent Inc. (NYSE: CTLT) for its Deuterated Tryptamine (CYB003).
Catalent is mainly involved in gene therapies, consumer health products, biologics, delivery technologies and drug development and manufacturing.
As per the agreement, Cyblin will be using Catalent’s proprietary Zydis orally disintegrating tablet (ODT) technology to deliver their novel deuterated tryptamine (CYB003). The drug will be used as a therapy for treatment-resistant psychiatric disorders.
The Zydis technology makes a freeze-dried tablet that disperses in the mouth without water immediately it’s placed in the mouth. This technology is recognized among the world’s best performing ODTs.
Cyblin is sure administering its drug in such a manner would have massive benefits because an ODT will allow pre-gastric delivery and prevent first pass metabolism. This will also increase the pharmacokinetic profile of the drug.
